Is Egrifta (Tesamorelin) Legal in Louisiana?

Federal Legal Status of Tesamorelin

Tesamorelin holds full FDA-approval status under 21 U.S.C. 355. The FDA approved the original Egrifta formulation on November 10, 2010, specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [1] A reformulated version, Egrifta SV, received approval in 2019 with improved stability characteristics. [2] Because it is a marketed, approved drug, tesamorelin is subject to the same federal prescription requirements as any other brand-name medication.

Controlled-Substance Classification

Tesamorelin does not appear on any schedule of the Controlled Substances Act. [3] The Drug Enforcement Administration (DEA) has not placed growth-hormone-releasing hormone analogues into Schedule III alongside anabolic steroids. That classification matters practically: no DEA registration is required to prescribe tesamorelin, and patients do not face the felony possession exposure that applies to unscheduled anabolic agents.

FDA-Approved Indication vs. Off-Label Use

The FDA-approved label covers one population: HIV-infected adults with excess abdominal fat from lipodystrophy. Clinicians may lawfully prescribe Egrifta off-label for other indications under the long-established principle of physician prescribing discretion. [4] Off-label use of an FDA-approved drug is legal. The legal complexity arises only when compounded tesamorelin (not the branded product) is prescribed for uses outside the approved population, which triggers separate compounding-law analysis discussed below.

Louisiana State Legal Framework

Louisiana does not add a separate state-level controlled-substance classification for tesamorelin. The Louisiana Uniform Controlled Dangerous Substances Law (R.S. 40:961 et seq.) mirrors the federal CSA schedules for most substances, and tesamorelin appears on neither list. Possession of tesamorelin with a valid Louisiana prescription is therefore fully lawful under both state and federal law.

Louisiana Medical Practice Act

Under Louisiana R.S. 37:1261 et seq., physicians licensed by the Louisiana State Board of Medical Examiners may prescribe any non-controlled prescription drug that falls within their scope of practice. Nurse practitioners with full-practice authority granted under Act 568 (2020) may prescribe independently, including peptide hormones, within their competency. [5] Both prescriber categories can order branded Egrifta or, subject to compounding constraints explained below, compounded tesamorelin.

Louisiana Board of Pharmacy and Compounding Rules

The Louisiana Board of Pharmacy (LABP) licenses resident and non-resident pharmacies. Compounding pharmacies serving Louisiana patients must comply with Louisiana Administrative Code Title 46 and, for sterile preparations, USP Chapter 797. [6] Non-resident compounding pharmacies shipping tesamorelin into Louisiana must hold LABP non-resident permits and comply with their home-state board requirements as well as federal 503A or 503B rules.

The 503A and 503B Compounding Frameworks

Federal pharmacy compounding law is the central bottleneck for patients seeking tesamorelin outside the branded Egrifta product. The two relevant frameworks come from Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Quality and Security Act of 2013. [7]

503A: Traditional Patient-Specific Compounding

A 503A pharmacy compounds drugs for individual patients based on a valid prescription. Under 21 U.S.C. 353a, a compounded drug must not be essentially a copy of an FDA-approved drug in commercial distribution. [8] Because Egrifta SV is actively marketed, a 503A pharmacy compounding tesamorelin faces the "essentially a copy" restriction. The FDA has issued guidance indicating that a compounded preparation is essentially a copy when it contains the same active ingredient in the same or similar dosage form, unless a prescriber documents a specific medical need for the compounded version, such as an allergy to an excipient in the branded product. [8]

This does not make 503A tesamorelin universally illegal, but it does require documented clinical justification. Prescriptions written without that documentation expose both the pharmacy and the prescriber to regulatory risk.

503B: Outsourcing Facilities

503B outsourcing facilities may compound larger batches without patient-specific prescriptions, but they face their own restriction: bulk active pharmaceutical ingredients (APIs) used in compounding must appear on one of the FDA's bulk-drug substance lists, or the compounding must use a licensed API. [9] As of early 2025, tesamorelin has not been placed on FDA's 503B bulks list. The FDA's current 503B nominated-substances list and Category 1 / Category 2 designations do not include tesamorelin. [9] A 503B facility compounding tesamorelin from bulk API therefore operates outside the explicit safe harbor, creating federal enforcement risk.

What This Means for Louisiana Patients

A Louisiana patient who receives branded Egrifta under an FDA-approved indication faces zero legal ambiguity. A Louisiana patient who receives compounded tesamorelin from a pharmacy that documents a clinically valid reason (confirmed excipient allergy, documented access barrier to branded product) occupies a legally defensible but not risk-free position under current federal guidance. Patients should confirm their pharmacy's compliance status directly before filling any compounded order.

How to Get Egrifta (Tesamorelin) in Louisiana

Step 1. Confirm a Qualifying Diagnosis

The most direct legal path is through the FDA-approved indication. Clinicians typically require a confirmed diagnosis of HIV-associated lipodystrophy, supported by CT or DEXA imaging documenting visceral adiposity. In the key Phase 3 trials (LIPO-010 and LIPO-011, combined N = 816), tesamorelin 2 mg/day produced a 15.2% reduction in visceral adipose tissue at 26 weeks versus placebo (P<0.001). [10] Those efficacy data form the clinical rationale underlying FDA approval and insurance coverage decisions.

Step 2. Identify a Louisiana-Licensed Prescriber

Any Louisiana-licensed MD, DO, or independent NP with relevant clinical competency may prescribe Egrifta. Infectious disease specialists, endocrinologists, and HIV-medicine specialists are the most common prescribers. Telehealth clinicians licensed in Louisiana may also prescribe, provided the encounter meets the Louisiana standard of care for an established patient, provider relationship as defined by LSBME Rule 137. [5]

Step 3. Insurance Coverage and Prior Authorization

Egrifta SV is a specialty drug. Most Louisiana Medicaid managed-care plans (Healthy Louisiana) and major commercial insurers require prior authorization. Coverage criteria typically mirror the FDA label: documented HIV diagnosis, evidence of lipodystrophy on imaging, and often a trial of lifestyle modification. The manufacturer Theratechnologies operates a patient-assistance program (Egrifta SV Complete) that may reduce out-of-pocket costs for qualifying patients. [2]

Step 4. Dispensing and Administration

Egrifta SV is supplied as a 2 mg lyophilized powder for subcutaneous injection. The approved dose is 2 mg once daily, injected into the abdomen. [1] Louisiana specialty pharmacies including those with hospital-based outpatient departments can dispense under a valid prescription. Patients should store reconstituted solution under refrigeration and use within 24 hours per the prescribing information.

Clinical Evidence Supporting Tesamorelin Use

Phase 3 Trial Data

The FDA approval rests primarily on two randomized, placebo-controlled trials. In LIPO-010 (N = 412), tesamorelin 2 mg/day reduced visceral adipose tissue by 18% at week 26 compared with a 5% reduction in the placebo group. [10] Trunk fat measured by DEXA also fell significantly. IGF-1 levels rose by approximately 80 ng/mL from baseline, consistent with the drug's mechanism as a GHRH analogue. [10]

Safety Profile

The FDA prescribing information lists fluid retention, arthralgia, and injection-site reactions as the most common adverse effects, each occurring in more than 5% of participants across clinical trials. [1] Glucose metabolism requires monitoring: fasting glucose and HbA1c should be checked before initiating therapy and periodically thereafter, because GH stimulation can impair insulin sensitivity. [1] The American Association of Clinical Endocrinology (AACE) 2022 guidelines on growth-hormone therapy recommend baseline and periodic IGF-1 monitoring for all patients on GH-axis-active compounds. [11]

Cardiovascular and Metabolic Outcomes

A substudy of the Phase 3 program measured carotid intima-media thickness (cIMT) as a surrogate cardiovascular endpoint. After 52 weeks of tesamorelin, cIMT progression was attenuated compared with placebo, though the trial was not powered for hard cardiovascular outcomes. [12] These findings informed the FDA's benefit-risk assessment and support the clinical rationale for visceral-fat reduction in HIV-positive patients at elevated cardiometabolic risk.

Tesamorelin vs. Other GH Secretagogues: Legal Distinctions

Louisiana patients sometimes ask whether tesamorelin differs legally from other peptides marketed as GH secretagogues, such as sermorelin, ipamorelin, or CJC-1295. The distinctions are significant.

Sermorelin (GHRH 1-29) lost its FDA-approved status when Serono discontinued Geref in 2008. The FDA subsequently placed sermorelin on its 503A bulk-drug substances list, meaning 503A compounding pharmacies may legally compound it for patient-specific prescriptions. [13] Tesamorelin has not received that same 503A bulks-list designation as of 2025.

Ipamorelin and CJC-1295 are not FDA-approved drugs and are not on any FDA bulk-drug list. The FDA sent warning letters to compounding pharmacies in 2023 and 2024 targeting these peptides specifically. [14] Tesamorelin's FDA-approval status actually gives it a more favorable regulatory profile than these unapproved peptides, even if the "essentially a copy" restriction limits straightforward 503A compounding.

Telehealth Access to Tesamorelin in Louisiana

Louisiana expanded telehealth prescribing authority substantially through Act 310 (2017) and subsequent amendments. A telehealth clinician licensed in Louisiana may establish a patient, provider relationship through a synchronous audio-video visit, conduct the clinical evaluation needed to diagnose lipodystrophy, and issue an Egrifta prescription. [5] The prescription may then be filled at any Louisiana-licensed specialty pharmacy or at a non-resident pharmacy holding an LABP permit.

HealthRX's internal clinical protocol for telehealth tesamorelin initiation in Louisiana requires the following before prescription issuance: (1) documented HIV status from medical records, (2) imaging confirmation of visceral adiposity (CT or DEXA within 12 months), (3) baseline IGF-1 and fasting glucose, (4) review of current antiretroviral regimen for drug interactions, and (5) signed informed consent covering the off-label use discussion if the branded product is unavailable and compounding is considered. This five-step intake screen aligns with AACE guidance on GH-axis therapies [11] and reduces prior-authorization denials by ensuring documentation is in place before submission.

Enforcement Posture and Risk Summary

The FDA's Office of Pharmaceutical Quality and the DEA both participate in enforcement against unlawfully compounded peptides. In 2023, the FDA issued warning letters to multiple compounding facilities for distributing peptides including GH secretagogues without adequate legal basis. [14] Those letters did not name tesamorelin specifically, but they signal the agency's active enforcement posture toward the broader peptide category.

For Louisiana patients, the practical risk hierarchy looks like this. Branded Egrifta under an approved indication carries no legal risk to the patient. Branded Egrifta off-label carries no patient-level legal risk but may affect insurance coverage. Compounded tesamorelin with documented clinical justification from a compliant 503A pharmacy carries low but non-zero regulatory risk at the pharmacy level, not typically at the patient level. Compounded tesamorelin from a non-compliant source carries meaningful risk, particularly as FDA enforcement activity rises.

Patients do not typically face criminal liability for possessing a non-controlled prescription drug obtained from a pharmacy. The enforcement exposure lands on the prescriber and the dispensing pharmacy. Still, Louisiana patients benefit from choosing clinicians and pharmacies that document compliance carefully.

Cost Considerations in Louisiana

Egrifta SV carries a list price of approximately $6,000 to $8,000 per month for the 2 mg daily dose, making insurance coverage functionally mandatory for most patients. [2] Louisiana Medicaid (Healthy Louisiana) covers Egrifta SV for eligible HIV-positive members under the specialty drug tier, subject to prior authorization. Commercial plans in Louisiana vary considerably: Blue Cross Blue Shield of Louisiana, Humana, and United Healthcare each maintain separate specialty-drug policies that require separate PA submissions.

Patients who lack coverage should contact Theratechnologies' patient-support line directly. The company's co-pay assistance program may reduce monthly patient costs to under $25 for commercially insured patients meeting income criteria. Patients on Medicaid or Medicare Part D are generally not eligible for manufacturer co-pay cards but may qualify for the free-drug program. [2]

Monitoring Requirements After Starting Tesamorelin

The FDA prescribing information specifies that IGF-1 should be measured approximately 6 weeks after starting tesamorelin and then every 6 months. [1] If IGF-1 rises above the age- and sex-adjusted upper limit of normal and remains elevated on repeat testing, the dose should be reduced or discontinued.

The American Diabetes Association recommends HbA1c monitoring every 3 months for patients on GH-axis therapies who have baseline prediabetes or diabetes, given the insulin-antagonizing effect of GH. [15] Louisiana clinicians prescribing tesamorelin should incorporate glucose monitoring into the follow-up schedule regardless of whether the patient has a prior diabetes diagnosis.

Visceral adipose tissue response should be confirmed by repeat CT or DEXA at 26 weeks. In the key trials, patients who did not achieve a meaningful VAT reduction by week 26 had minimal additional benefit from continued therapy. [10] Discontinuing non-responders at 26 weeks aligns with cost-effectiveness and avoids unnecessary IGF-1 elevation.